Targeted therapeutics that suppress melanoma growth such as BRAF inhibitors Vemurafenib or Dabrafenib, or the direct MEK inhibitors Cobimetinib or Tranetinib,36 have revolutionized metastatic melanoma therapy and have at last improved patient survival. The gene discussed is MAP2K7; the disease is melanoma.